Basic Study
Copyright ©The Author(s) 2017.
World J Gastroenterol. Jul 7, 2017; 23(25): 4559-4568
Published online Jul 7, 2017. doi: 10.3748/wjg.v23.i25.4559
Figure 1
Figure 1 Rosuvastatin attenuated changes in body weight and the disease activity index in dextran sodium sulphate-induced colitis model. In mice, acute colitis was induced by oral DSS administration in drinking water for 7 d. Rosuvastatin (0.3 mg/kg per day) was administered orally before and after DSS administration for 21 d in the rosuvastatin-treated group. A: Changes in body weight during DSS administration in mice treated with and without rosuvastatin. Mice in the rosuvastatin group showed less weight loss than mice in DSS-induced colitis model; B: Disease activity index (sum of weight change, gross bleeding, and stool consistency scores) in mice treated with and without rosuvastatin. The rosuvastatin group had a lower disease activity index than untreated mice. Data are expressed as mean ± SE. aP < 0.05 vs DSS group. DSS: Dextran sodium sulphate; Ro: Rosuvastatin.